by David Wallace Hi, my name is David, and I am a polycythemia vera (PV) warrior. PV is a rare blood cancer. To me, living with a rare disease is not just a medical journey; it’s a testament to resilience and the power of community. Rare Disease Day, for me, is more than just a […]
What is Blast Phase Myeloproliferative Neoplasm?
Abstract Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for essential thrombocythemia, 3–7% for polycythemia vera, and 9–13% for primary myelofibrosis. Diagnosis of MPN-BP requires the presence of ≥20% circulating or bone marrow blasts; a lower level of excess blasts […]
MPN Patient Advocate: Strategies for Self-Advocacy and Better Health Outcomes
by David Wallace Living with myeloproliferative neoplasms (MPNs) can be challenging both physically and emotionally. MPNs are rare blood cancers that require continuous management and care. The three main types of MPNs are myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). As a patient, it is crucial to become your own advocate in order […]
Overcoming fear: How avid hiker and PV patient Gary put one foot in front of the other until he found a treatment that worked
Part of my inspiration for becoming an advocate and sharing information on PV Reporter is to encourage others living with PV to educate themselves and maintain a positive mindset, despite their diagnosis. I know how it feels to hear the words, “you have cancer,” and how that fear can impact one’s outlook on life. Throughout […]
Ojjaara, FDA Approved for Treatment of Myelofibrosis with Anemia
September 15, 2023 Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease, and over 30% will discontinue […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 42
- Next Page »
